Intestinal in vitro transport assay combined with physiologically based kinetic modeling as a tool to predict bile acid levels in vivo

Bile acid homeostasis is vital for numerous metabolic and immune functions in humans. The enterohepatic circulation of bile acids is extremely efficient, with ~95% of the intestinal bile acids being reabsorbed. Disturbing intestinal bile acid uptake is expected to substantially affect intestinal and systemic bile acid levels. Here, we aimed to predict the effects of Apical Sodium-Dependent Bile Acid Transporter (ASBT)-inhibition on systemic plasma levels. For this, we combined the in vitro Caco-2 cell transport assays with physiologically based (PBK) modeling. For this proof-of-principle study we used the selective ASBT-inhibitor odevixibat (ODE) as a model compound. Caco-2 cells grown on culture inserts were used to obtain transport kinetic parameters of glycocholic acid (GCA). The apparent Michaelis Menten constant (Km,app), apparent maximal intestinal transport rate (Vmax,app) and ODE's inhibitory constant (Ki) were determined for GCA. These kinetic parameters were incorporated in a PBK model and used to predict the ASBT inhibition effects on plasma bile acid levels. GCA is transported over Caco-2 cells in an active and sodium-dependent manner, indicating the presence of functional ASBT. ODE inhibited GCA transport dose-dependently. The PBK model predicted that oral doses of ODE reduced conjugated bile acid levels in plasma. Our simulations match in vivo data and provide a first proof-of-principle for the incorporation of active intestinal bile acid uptake in a bile acid PBK model. This approach could in future be of use to predict the effects of other ASBT-inhibitors on plasma and intestinal bile acid levels.

Caco-2; apical sodium dependent bile acid transporter (ASBT); bile acids and salts; odevixibat; quantitative-in-vitro-to-in-vivo extrapolation (QIVIVE).